



**Document No.**  
PVPI\_SPV.19.01\_A01  
**Version**  
7.0

The collection, storage, processing and worldwide reporting of personal data connected to adverse events is required by international drug safety regulations. During this process, personal data is protected in accordance to the General Data Protection Regulations GDPR, REGULATION (EU) 2016/679 or other international legislation. As an additional precaution, certain personal data is made anonymous in, or withheld from, individual reports of safety data.



**Title:** **GE Healthcare Pharmaceutical Diagnostics Adverse Event Intake Form**

**PART 5. ADDITIONAL DETAILS OF THE ADVERSE EVENT** *(Include all available details about clinical course and any other details not specified in other fields. Include treatment for AE, if applicable. For treatment medication, include indication, start and stop dates, and route. For non-interventional studies, include Study ID, Patient ID, and Center or Site ID.)*

--

**PART 6. CONCOMITANT MEDICATION INFORMATION (Include prescription, over-the-counter, and herbal medications)**

Trade name or Generic name	Indication	Start date	Stop Date <i>(enter "ongoing" if no stop date)</i>	Dose (Units) & Frequency	Route

**PART 7. RELEVANT MEDICAL CONDITIONS / HISTORY**

Condition <i>(if information does not fit, add to 'Additional Details of the AE' section)</i>	Medical History (MH) OR Current Condition (CC)	Start Date	Stop Date
	MH    CC		
	MH    CC		
	MH    CC		
	MH    CC		

**PART 8. SPECIFIED RISK FACTORS**

	Risk Factor?	Start Date	Stop date	Specify allergy/Comments
Allergies	Y   N   Unk			
Asthma	Y   N   Unk			
Dehydration	Y   N   Unk			
Renal Impairment	Y   N   Unk			

**PART 9. RELEVANT DIAGNOSTIC TESTS (INCLUDING VITAL SIGNS)**

Test name	Date	Results <i>(include units)</i>	Lab normal values <i>(include units)</i>

NAME	SIGNATURE	DATE

Please send completed form to the Central Safety Unit (CSU) at [gpv.drugsafety@ge.com](mailto:gpv.drugsafety@ge.com)

### Drop-down Menu Quick Reference

Gender	Pregnant	Race / Ethnicity	Seriousness Criteria
<ul style="list-style-type: none"> <li>• Male</li> <li>• Female</li> <li>• Other</li> <li>• Unknown</li> </ul>	<ul style="list-style-type: none"> <li>• Yes</li> <li>• No</li> <li>• Unknown</li> </ul>	<ul style="list-style-type: none"> <li>• Caucasian</li> <li>• Black</li> <li>• Asian</li> <li>• Other</li> <li>• African American</li> <li>• American Indian</li> <li>• Alaska Native</li> <li>• Native Hawaiian</li> <li>• Other Pacific Islander</li> <li>• White</li> <li>• Hispanic</li> <li>• Unknown</li> </ul>	<ul style="list-style-type: none"> <li>• Death</li> <li>• Life-threatening</li> <li>• Hospitalization</li> <li>• Prolonged Hospitalization</li> <li>• Disability</li> <li>• Congenital Anomaly</li> <li>• Important Medical Event</li> <li>• Non-serious</li> <li>• Unknown</li> </ul>

Outcome	Relationship to Suspect Product	Formulation
<ul style="list-style-type: none"> <li>• Recovered</li> <li>• Recovering</li> <li>• Not Recovered</li> <li>• Recovered with Sequelae</li> <li>• Death</li> <li>• Unknown</li> </ul>	<ul style="list-style-type: none"> <li>• Not Related</li> <li>• Not Reported</li> <li>• Related</li> </ul>	<ul style="list-style-type: none"> <li>• Solution for Injection</li> <li>• Solution for injection via pre-filled syringe</li> <li>• Oral Solution</li> <li>• Other (specify in Part 5)</li> <li>• Unknown</li> </ul>

### Date Format Quick Reference

dd-Mmm-yyyy

**Receipt Date** LSU or LSUs  
Representative's awareness date